Sch-37370

Sch-37370

SCHEMBL3071641

CC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTAFR P25105 10/20 1.00
SLC6A15 Q9H2J7 10/20 1.00
HRH1 P35367 5/20 1.00
FNTA P49354 2/20 1.00
FNTB P49356 2/20 1.00
MEN1 O00255 1/20 0.76
NPC1 O15118 1/20 0.76
CACNA1F O60840 1/20 0.76
NR1I2 O75469 1/20 0.76
GMNN O75496 1/20 0.76
USP2 O75604 1/20 0.76
ABCB11 O95342 1/20 0.76
LMNA P02545 1/20 0.76
TP53 P04637 1/20 0.76
CHRM2 P08172 1/20 0.76
ABCB1 P08183 1/20 0.76
CYP3A4 P08684 1/20 0.76
ADORA3 P0DMS8 1/20 0.76
CYP2C8 P10632 1/20 0.76
CYP2D6 P10635 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sch-37370 SCHEMBL29754039 1.00 PTAFR (1.00) PTAFRSLC6A15HRH1FNTAFNTB
Sch-37370 SCHEMBL29626524 1.00 PTAFR (1.00) PTAFRSLC6A15HRH1FNTAFNTB
SCHEMBL8878121 0.93 SLC6A15 (0.86) PTAFRSLC6A15HRH1FNTAFNTB
SCHEMBL8880503 0.91 PTAFR (1.00) PTAFRSLC6A15HRH1FNTAFNTB
SCHEMBL3367280 0.90 SLC6A15 (0.82) PTAFRSLC6A15HRH1FNTAFNTB
SCHEMBL8880239 0.90 PTAFR (1.00) PTAFRSLC6A15HRH1FNTAFNTB
SCHEMBL8878295 0.89 SLC6A15 (0.80) PTAFRSLC6A15HRH1FNTAFNTB
SCHEMBL8889578 0.89 SLC6A15 (0.79) PTAFRSLC6A15HRH1FNTAFNTB
SCHEMBL8878098 0.89 SLC6A15 (1.00) PTAFRSLC6A15HRH1FNTAFNTB
SCHEMBL8878015 0.89 SLC6A15 (0.86) PTAFRSLC6A15HRH1FNTAFNTB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021086133-A1 TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF (주)제이디바이오사이언스 2021-05-06 WO claimed
EP-0469477-B1 Antiallergic combination HOFFMANN LA ROCHE (CH) 1995-09-20 EP claimed
EP-0270818-B1 Benzo(5,6)cycloheptapyridines, compositions and method of use SCHERING CORP (US) 1994-12-28 EP claimed
EP-0330673-A1 BENZO 5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE SCHERING CORPORATION (US) 1989-09-06 EP claimed
US-4826853-A ANTIALLERGENS, ANTIINFLAMMATORY AGENTS SCHERING CORPORATION (US) 1989-05-02 US claimed
EP-0270818-A1 Benzo(5,6)cycloheptapyridines, compositions and method of use SCHERING CORPORATION (US) 1988-06-15 EP claimed
WO-1988003138-A1 BENZO[5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE SCHERING CORPORATION (US) 1988-05-05 WO claimed
CN-119780305-A Method for analyzing and detecting related substances of desloratadine 浙江东亚药业股份有限公司 2025-04-08 CN disclosed
US-20230002349-A1 TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF JD BIOSCIENCE INC. (KR) 2023-01-05 US disclosed
WO-2021086133-A1 TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF (주)제이디바이오사이언스 2021-05-06 WO disclosed
WO-2021086133-A1 TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF (주)제이디바이오사이언스 2021-05-06 WO disclosed
US-20100273757-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS LABORATORIOS ALMIRALL, S.A. 2010-10-28 US disclosed
US-7790728-B2 Pyrazine derivatives useful as adenosine receptor antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2010-09-07 US disclosed
WO-1992006970-A1 BIS-BENZO CYCLOHEPTA PIPERIDYLIDENE, PIPERIDINE AND PIPERAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE SCHERING CORPORATION (US) 1992-04-30 WO disclosed
US-5089496-A Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies SCHERING CORPORATION (US) 1992-02-18 US disclosed
WO-1992000293-A1 BIS-BENZO OR BENZOPYRIDO CYCLO HEPTA PIPERIDENE, PIPERIDYLIDENE AND PIPERAZINE COMPOUNDS AND COMPOSITIONS SCHERING CORPORATION (US) 1992-01-09 WO disclosed
EP-0330673-A1 BENZO 5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE SCHERING CORPORATION (US) 1989-09-06 EP disclosed
US-4826853-A ANTIALLERGENS, ANTIINFLAMMATORY AGENTS SCHERING CORPORATION (US) 1989-05-02 US disclosed
EP-0270818-A1 Benzo(5,6)cycloheptapyridines, compositions and method of use SCHERING CORPORATION (US) 1988-06-15 EP disclosed
WO-1988003138-A1 BENZO[5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE SCHERING CORPORATION (US) 1988-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002349-A1 TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TPH1, SLC6A4, TPH2 PTAFR 1723/4885SLC6A15 28/4885HRH1 1035/4885
US-20100273757-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS ADORA2B, ADORA2A, ADORA1 PTAFR 474/4885SLC6A15 2539/4885HRH1 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.